GBA Presents: THE GREEN MARKET

Van I got a question-- I am fascinated by this CHWY ultimate low was $50.11 cents <-- RIGGED! it never ever hit 50 what happened to those options in that case.?

People are telling me they are worthless WHAT!
 
ChargePoint named a Best Idea, top EV charging pick for 2022 at Cowen 09:17 CHPT Cowen analyst Gabe Daoud named ChargePoint as his Best Idea for 2022 and top EV charging pick given what he sees as "it's market leading position." 2021 was defined by challenging equity performance across the EV ecosystem, but fundamentals remain strong and momentum is likely to continue as e-mobility further accelerates in 2022, said Daoud, who has an Outperform rating and $37 price target on the shares.
 
I realize I am doing two things at once raising this cash and hoping for a new idea.

It's not making for a clear head.

The stk with the best fundamentals that we are following,. the best chart (albeit low vol) and the best low risk.. is Delta Apparel I'm just held back by the insider sell.... And apparently on the AMAX exchange does that still exist?

AMEX
DLA> DELTA APPAREL INC COM
Symbol
Last Price x Size / Exch
29.50


Bid x size
29.05x 100P

Ask x size
30.45x 100P
 
stonedinvestor said:
WOW!

Pfizer to acquire Arena for $100 per share in all-cash transaction 06:48 PFE, ARNA Pfize (PFE) and Arena Pharmaceuticals (ARNA) announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Under the terms of the agreement, Pfizer will acquire all the outstanding shares of Arena for $100 per share in an all-cash transaction for a total equity value of approximately $6.7B. The boards of directors of both companies have unanimously approved the transaction. "The proposed acquisition of Arena complements our capabilities and expertise in Inflammation and Immunology, a Pfizer innovation engine developing potential therapies for patients with debilitating immuno-inflammatory diseases with a need for more effective treatment options," said Mike Gladstone, Global President & General Manager, Pfizer Inflammation and Immunology. "Utilizing Pfizer's leading research and global development capabilities, we plan to accelerate the clinical development of etrasimod for patients with immuno-inflammatory diseases." Arena has built a development program for etrasimod, including two Phase 3 studies in ulcerative colitis, UC, a Phase 2/3 program in Crohn's Disease, a planned Phase 3 program in atopic dermatitis, and ongoing Phase 2 studies in eosinophilic esophagitis and alopecia areata. In addition, Arena's pipeline includes two development-stage cardiovascular assets, temanogrel and APD418. Temanogrel is currently in Phase 2 for the treatment of microvascular obstruction and Raynaud's phenomenon secondary to systemic sclerosis. APD418 is currently in Phase 2 for acute heart failure. Pfizer expects to finance the transaction with existing cash on hand.

.....
More...

Pfizer was my one and only ‘mini-savante’ moment of 2021 ;)
I think it may also have some fallback on at least some shift to growth?
 
You must log in or register to reply here.
Back
Top